Results 121 to 130 of about 268 (222)

[Pathophysiology of hypervitaminosis B12: from origin to clinical event. Scoping review]. [PDF]

Rev Med Inst Mex Seguro Soc
Fernández-Téllez B, Franco-Rico JA, Valdez-Martínez E.   +2 more
europepmc   +1 more source

First‐In‐Human Study: Dose Expansion of E7130 in Urothelial Carcinoma and Squamous Cell Carcinoma of the Head and Neck

Cancer Science, Volume 117, Issue 8, Page 2247-2258, August 2026.
The dose escalation part of the first‐in‐human study of E7130 in patients with advanced solid tumors determined the Recommended Phase 2 Dose of E7130 (480 μg/m2 Q3W). The dose expansion part (presented here) examined safety/preliminary efficacy in patients with squamous cell carcinoma of the head and neck and urothelial carcinoma.
Nobuaki Matsubara, Ken Saijo, Yasushi Shimizu, Susumu Okano, Kenji Nakano, Naoki Nishio, Tomoyuki Otsuka, Hirofumi Kuno, Takuma Miura, Tomoki Kubota, Hiroki Ikezawa, Yuko Umetsu, Ken Ito, Abraham Apfel, Yuanqing Ye, Yoshitaka Honma   +15 more
wiley   +1 more source

Following the roadmap outlined by the World health Organization: Innovation for the control of chronic noncommunicable diseases [PDF]

Biomedica
Peña-Silva RA, Reyes-González JS.
europepmc   +1 more source

Female sexual dysfunction in chronic obstructive pulmonary disease. [PDF]

Colomb Med (Cali), 2023
Arzu Özkarafakılı M, Kutsal C.
europepmc   +1 more source

MTAP Deficiency as a Metabolic Vulnerability in Cancer: Implications for Synthetic Lethal Therapy

Cancer Science, Volume 117, Issue 8, Page 2085-2097, August 2026.
MTAP deletion creates a therapeutically actionable metabolic vulnerability through MTA accumulation and PRMT5 dependency. This review summarizes the biochemical basis of MTAP‐directed synthetic lethality, emerging PRMT5/MAT2A inhibitors, clinicogenomic features of MTAP‐deleted tumors, and future strategies for precision oncology.
Hiroaki Ikushima, Hidenori Kage
wiley   +1 more source

[National recommendations on pediatric donation]. [PDF]

An Pediatr (Engl Ed), 2020
Rodríguez Núñez A, Pérez Blanco A, Grupo de Trabajo de la AEP-ONT, Miembros del Grupo de Trabajo de la AEP-ONT, por orden alfabético.   +4 more
europepmc   +1 more source

Restorative versus non‐restorative total proctocolectomy: Who doesn't pouch and how do they do?

Colorectal Disease, Volume 28, Issue 8, August 2026.
Abstract Aim Literature comparing total proctocolectomy with permanent end ileostomy (TPC‐EI) and IPAA in patients with UC is sparse. We aimed to (a) elucidate reasons for non‐restorative surgery in ulcerative colitis (UC), (b) describe the incidence of perineal wound complications and (c) assess differences in short‐term outcomes between groups.
Imran Khan, Nicholas G. Berger, Arielle Kanters, Olga Lavryk, Jeremy Lipman, Scott R. Steele, David Liska, Stefan D. Holubar   +7 more
wiley   +1 more source

Adherence to antihypertensive treatment in patients at a tertiary hospital in Lima, Peru. [PDF]

Rev Peru Med Exp Salud Publica
Aguilar-Lizarme A, Amado-Tineo J.
europepmc   +1 more source

[Modifications in self-care, quality of life and therapeutic adherence in patients with rheumatoid arthritis during the SARS-CoV-2 pandemic treated by telehealth]. [PDF]

Rev Colomb Reumatol, 2022
Hernández-Zambrano SM, Castiblanco-Montañez RA, Valencia Serna AM, Nonzoque Toro V, Sánchez Camargo MP, Restrepo Rodríguez LN, Rodríguez-Vargas GS, Villareal L, Rubio-Rubio JA, Quintero-Muñoz E, Gómez Pineda MA, Chávez-Chavéz J, Rivera-Triana D, Casanova R, Rojas-Villarraga A, Santos-Moreno P.   +15 more
europepmc   +1 more source

Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE‐JP Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6595-6606, August 2026.
ABSTRACT Aims There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon‐like peptide‐1 receptor (GLP‐1R) dual agonist with the potential to induce greater weight reductions than GLP‐1R mono‐agonists. We report the design and baseline participant characteristics of the
Koutaro Yokote, Toshimasa Yamauchi, Yasushi Fukushima, Yoji Takatsuka, Marie Kato, Shijia Yan, Takayoshi Inoue, Luiza Borowska, Martina Brueckmann, Wataru Ogawa, on behalf of the SYNCHRONIZE‐JP Trial Investigators   +10 more
wiley   +1 more source